Cargando…

Emerging roles of the solute carrier family in pancreatic cancer

Pancreatic cancer is a gastrointestinal tumor with a high mortality rate, and advances in surgical procedures have only resulted in limited improvements in the prognosis of patients. Solute carriers (SLCs), which rank second among membrane transport proteins in terms of abundance, regulate cellular...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Zijian, Xu, Jin, Liang, Chen, Meng, Qingcai, Hua, Jie, Wang, Wei, Zhang, Bo, Liu, Jiang, Yu, Xianjun, Shi, Si
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7989705/ https://www.ncbi.nlm.nih.gov/pubmed/33783998 http://dx.doi.org/10.1002/ctm2.356

Ejemplares similares

The role of ferroptosis regulators in the prognosis, immune activity and gemcitabine resistance of pancreatic cancer
por: Tang, Rong, et al.
Publicado: (2020)

Role of Damage DNA-Binding Protein 1 in Pancreatic Cancer Progression and Chemoresistance
por: Zhang, Yiyin, et al.
Publicado: (2019)

The role of m6A-related genes in the prognosis and immune microenvironment of pancreatic adenocarcinoma
por: Tang, Rong, et al.
Publicado: (2020)

Circular RNA in pancreatic cancer: a novel avenue for the roles of diagnosis and treatment
por: Rong, Zeyin, et al.
Publicado: (2021)

Role of tumor mutation burden-related signatures in the prognosis and immune microenvironment of pancreatic ductal adenocarcinoma
por: Tang, Rong, et al.
Publicado: (2021)

The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications
por: Liu, Xiaomeng, et al.
Publicado: (2019)

Identification of the Roles of a Stemness Index Based on mRNA Expression in the Prognosis and Metabolic Reprograming of Pancreatic Ductal Adenocarcinoma
por: Tang, Rong, et al.
Publicado: (2021)

Current status and dilemma of second-line treatment in advanced pancreatic cancer: is there a silver lining?
por: Hua, Jie, et al.
Publicado: (2018)

Hyperdense Pancreatic Ductal Adenocarcinoma: Clinical Characteristics and Proteomic Landscape
por: Xu, He, et al.
Publicado: (2021)

From the Immune Profile to the Immunoscore: Signatures for Improving Postsurgical Prognostic Prediction of Pancreatic Neuroendocrine Tumors
por: Wei, Miaoyan, et al.
Publicado: (2021)

Prognostic value of circulating tumor DNA in pancreatic cancer: a systematic review and meta-analysis
por: Fang, Zengli, et al.
Publicado: (2020)

Ferroptosis: At the Crossroad of Gemcitabine Resistance and Tumorigenesis in Pancreatic Cancer
por: Yang, Jianhui, et al.
Publicado: (2021)

PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications
por: Zhu, Heng, et al.
Publicado: (2020)

GPx1 is involved in the induction of protective autophagy in pancreatic cancer cells in response to glucose deprivation
por: Meng, Qingcai, et al.
Publicado: (2018)

A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma
por: Zhang, Yiyin, et al.
Publicado: (2019)

Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma
por: Tang, Rong, et al.
Publicado: (2021)

Nab-paclitaxel plus gemcitabine as first-line treatment for advanced pancreatic cancer: a systematic review and meta-analysis
por: Zhang, Yiyin, et al.
Publicado: (2019)

Complex roles of the stroma in the intrinsic resistance to gemcitabine in pancreatic cancer: where we are and where we are going
por: Liang, Chen, et al.
Publicado: (2017)

Mechanical Regulation of Redox Balance via the Induction of the PIN1/NRF2/ARE Axis in Pancreatic Cancer
por: Liang, Chen, et al.
Publicado: (2023)

A miR-146a-5p/TRAF6/NF-kB p65 axis regulates pancreatic cancer chemoresistance: functional validation and clinical significance
por: Meng, Qingcai, et al.
Publicado: (2020)

Turning towards nonimmunoreactive tumors: Evaluation of cancer-associated fibroblasts enables prediction of the immune microenvironment and treatment sensitivity in pancreatic cancer
por: Lu, Siyuan, et al.
Publicado: (2022)

Integrated analysis revealed hypoxia signatures and LDHA related to tumor cell dedifferentiation and unfavorable prognosis in pancreatic adenocarcinoma: Hypoxia in PDAC
por: Dong, Mingwei, et al.
Publicado: (2023)

Construction of a novel risk model based on the random forest algorithm to distinguish pancreatic cancers with different prognoses and immune microenvironment features
por: Lei, Yalan, et al.
Publicado: (2021)

The value of a metabolic reprogramming-related gene signature for pancreatic adenocarcinoma prognosis prediction
por: Tan, Zhen, et al.
Publicado: (2020)

The promising role of noncoding RNAs in cancer-associated fibroblasts: an overview of current status and future perspectives
por: Fang, Zengli, et al.
Publicado: (2020)

Circular RNA CircEYA3 induces energy production to promote pancreatic ductal adenocarcinoma progression through the miR-1294/c-Myc axis
por: Rong, Zeyin, et al.
Publicado: (2021)

Cuproptosis-Related Gene DLAT as a Novel Biomarker Correlated with Prognosis, Chemoresistance, and Immune Infiltration in Pancreatic Adenocarcinoma: A Preliminary Study Based on Bioinformatics Analysis
por: Fang, Zengli, et al.
Publicado: (2023)

Metabolic reprogramming of cancer-associated fibroblasts in pancreatic cancer contributes to the intratumor heterogeneity of PET-CT
por: Meng, Qingcai, et al.
Publicado: (2023)

The Role of PDGFRA in Predicting Oncological and Immune Characteristics in Pancreatic Ductal Adenocarcinoma
por: Wu, Zijian, et al.
Publicado: (2022)

Diagnostic and prognostic value of carcinoembryonic antigen in pancreatic cancer: a systematic review and meta-analysis
por: Meng, Qingcai, et al.
Publicado: (2017)

Radical antegrade modular pancreatosplenectomy (RAMPS) versus standard retrograde pancreatosplenectomy (SRPS) for resectable body and tail pancreatic adenocarcinoma: protocol of a multicenter, prospective, randomized phase III control trial (CSPAC-3)
por: Li, Jialin, et al.
Publicado: (2023)

RNA N6-methyladenosine demethylase FTO promotes pancreatic cancer progression by inducing the autocrine activity of PDGFC in an m(6)A-YTHDF2-dependent manner
por: Tan, Zhen, et al.
Publicado: (2022)

Ferroptosis, necroptosis, and pyroptosis in anticancer immunity
por: Tang, Rong, et al.
Publicado: (2020)

Comprehensive analysis of the prognosis and immune infiltration landscape of RNA methylation-related subtypes in pancreatic cancer
por: Lu, Siyuan, et al.
Publicado: (2022)

Mitochondria-Related Transcriptome Characterization Associated with the Immune Microenvironment, Therapeutic Response and Survival Prediction in Pancreatic Cancer
por: Dong, Jia, et al.
Publicado: (2023)

Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives
por: Mao, Xiaoqi, et al.
Publicado: (2021)

Diagnostic Accuracy of a CA125-Based Biomarker Panel in Patients with Pancreatic Cancer: A Systematic Review and Meta-Analysis
por: Meng, Qingcai, et al.
Publicado: (2017)

Signaling pathways in cancer‐associated fibroblasts: recent advances and future perspectives
por: Fang, Zengli, et al.
Publicado: (2022)

TCF7L2 positively regulates aerobic glycolysis via the EGLN2/HIF-1α axis and indicates prognosis in pancreatic cancer
por: Xiang, Jinfeng, et al.
Publicado: (2018)

Targeting neoadjuvant chemotherapy-induced metabolic reprogramming in pancreatic cancer promotes anti-tumor immunity and chemo-response
por: Tang, Rong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hhhcc6hmepvo04j0tsf768gqei